Updated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte’s epacadostat combined with Merck’s Keytruda to treat patients with metastatic melanoma.

The new data, culled from the study Incyte calls ECHO-202, look good, matching or exceeding investor expectations. Here’s a rundown:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a Melanoma patient who has gone through 38 rounds of IL2 in 2010 and wondering when the Melanoma would become active again in my body, well I don’t have that on my mind anymore, I found out Thursday August 31 that it’s back, I was seeking some information, doing a little research for my options.
    I find it disgusting that you would withhold such vital information from the public and demand a ransom for it, I will be sure to tell everyone I know to avoid your website and cancel their subscriptions if they have one.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy